Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Country's Decision or any other Communication
(DEC)
last updated: 03 May 2021
No
Approval to Conduct Confined Field trial of a Novel Rift Valley Fever Vaccine in Sheep, Goats, Cattle and Camels
EN
25 Nov 2016
No
- Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
No
No
-
Nairobi,Person:Dr. George WarimwePrincipal Scientist,
, KenyaPhone: +1865617622,Fax: +1865617608,Email: gwarimwe@kemri-wellcome.org,Website:Related OrganizationInternational Livestock Research Institute (ILRI) /The Jenner Institute, University of Oxford, United Kingdom ()
Yes
No
No
Approval of the import and/or use of the LMO(s) with conditions
For the purposes of conducting confined field trials (CFTs) only.
EN
The application is for Contained Use
EN
-
BCH-LMO-SCBD-115616-2 Living Modified Organism Rift Valley Fever Virus DIVA vaccineInternational Livestock Research Institute (ILRI) /The Jenner Institute, University of Oxford, United Kingdom | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-RA-KE-115659-1 Risk Assessment generated by a regulatory process Summary risk assessment report on the application for Confined Field Trial of a novel Rift Valley Fever Vaccine in sheep, goats, cattle and camelsRift Valley Fever Virus DIVA vaccine | ChAd Y25, Production of medical or pharmaceutical compounds (human or animal)
- Rift Valley Fever Vaccine- Decision Document.pdf [ English ]
